Answers are grounded in this paper and cite their sources.
Molecular imaging (MI) is an unavoidable technology in precision medicine, enabling the picturing of biological activities at cellular and cellular levels. Positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT), offer harmonizing viewpoints on physiology, metabolism, as well as anatomy. Integration of these methods through hybrid platforms provides a strong, multidimensional approach for timely disease diagnosis, tailored diagnosis, and medication monitoring. This review studies the fashionable background and clinical importance of PET, MRI, and SPECT in accurate screening, emphasizing their roles in oncology, neurology, cardiology, and so on. We examine new progresses in radiotracer formation, quantifiable imaging biomarkers, and AI-aided image analyzing, which are enhancing sensitivity, precision, and prognosis precision. The review moreover studies imminent progresses comprising dynamic multimodal imaging, radiogenomics, immune-targeted imaging, and modified theranostics. Nevertheless such progresses, like infrastructural limitations, radiotracer shortage, data amalgamation particulars, and ethical dilemmas. These problems must be overwhelmed to attain reasonable and scalable application of MI methods across many sustainable healthcare systems. MI is established to progress from an additional diagnostic technique to a proactive, adaptive instrument significant to tailored healthcare. Through the combination of biological awareness and technology progress, PET, MRI, and SPECT will continue in their progression as vital elements of the precision drug framework altering our approaches of disease detection, understanding, and medication.
No takes yet. Share an insight, caveat, or question.
Parveen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: